MicroRNA Signature Predicted Breast Cancer Survival, Bone Metastasis
This video highlights a novel scoring system using microRNA signatures that predicted poor overall survival and bone metastasis in patients with luminal A breast cancer.
In this video, Kazuaki Takabe, MD, PhD, of Roswell Park Cancer Institute in Buffalo, New York, discusses a study that found that a scoring system using microRNA signatures predicted poor overall survival and bone metastasis in patients with luminal A breast cancer.
The researchers examined 1,051 patients from The Cancer Genome Atlas and discovered that microRNA signatures miR-19a, miR-93, and miR-106a were predictive for these outcomes. The results were validated in two separate cohorts.
Takabe presented the findings at the 2017 American Association for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
